X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) has granted inducement awards to new employees under its 2019 Inducement Plan. The awards consist of options to purchase 271,764 shares of common stock at an exercise price of $0.5002 per share, equal to the closing price on October 31, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha concesso premi di incentivazione ai nuovi dipendenti secondo il suo Piano di Incentivazione del 2019. I premi consistono in opzioni per acquistare 271.764 azioni ordinarie a un prezzo di esercizio di $0,5002 per azione, equivalente al prezzo di chiusura del 31 ottobre 2024. Le opzioni hanno una durata di dieci anni e verranno maturate nell'arco di quattro anni, con il 25% che matura dopo 12 mesi e il restante che matura mensilmente per 36 mesi, subordinatamente a un impiego continuato. Questi premi sono stati concessi in conformità alla Regola di Quotazione Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha otorgado premios de incentivo a nuevos empleados bajo su Plan de Incentivo de 2019. Los premios consisten en opciones para comprar 271,764 acciones ordinarias a un precio de ejercicio de $0.5002 por acción, igual al precio de cierre del 31 de octubre de 2024. Las opciones tienen un plazo de diez años y se consolidarán durante cuatro años, con el 25% consolidándose después de 12 meses y el resto consolidándose mensualmente durante 36 meses, condicionado a la continuidad del empleo. Estas concesiones se realizaron de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR)는 2019년 유도 계획에 따라 신규 직원에게 유도 상을 부여했습니다. 이 상은 271,764 주식을 $0.5002의 행사 가격으로 구매할 수 있는 옵션으로 구성되어 있으며, 이는 2024년 10월 31일의 종가와 동일합니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 부여되며, 12개월 후 25%가 부여되고 나머지는 36개월 동안 매월 부여되며, 지속적인 고용에 따라 달라집니다. 이러한 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
X4 Pharmaceuticals (XFOR) a accordé des récompenses d'incitation à de nouveaux employés dans le cadre de son Plan d'Incitation de 2019. Les récompenses consistent en des options pour acheter 271.764 actions ordinaires à un prix d'exercice de $0,5002 par action, correspondant au prix de clôture du 31 octobre 2024. Les options ont une durée de dix ans et se déploieront sur quatre ans, avec 25% se déployant après 12 mois et le reste se déployant mensuellement sur 36 mois, sous condition d'un emploi continu. Ces attributions ont été faites conformément à la règle de cotation Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) hat neuen Mitarbeitern im Rahmen seines 2019 Incentive Plans Anreizvergaben gewährt. Die Vergaben bestehen aus Optionen zum Kauf von 271.764 Aktien zum Ausübungspreis von $0,5002 pro Aktie, was dem Schlusskurs vom 31. Oktober 2024 entspricht. Die Optionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre auslaufen, wobei 25% nach 12 Monaten und der Rest monatlich über 36 Monate gewährt wird, abhängig von der Fortsetzung des Arbeitsverhältnisses. Diese Zuwendungen wurden gemäß der Nasdaq Listing Regel 5635(c)(4) gewährt.
- None.
- None.
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on October 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 271,764 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares were included in X4 Pharmaceuticals (XFOR) inducement grants on October 31, 2024?
What is the exercise price for XFOR's October 2024 inducement stock options?
What is the vesting schedule for XFOR's October 2024 inducement grants?
